Wireless PH Monitoring Systems segmentation by application delineates six discrete demand pockets that together shape the 2023 global market. Gastroesophageal Reflux Disease (GERD) diagnostics commands the largest revenue share—nearly 42 %—because prolonged ambulatory pH recording is still the de facto surrogate for reflux episodes, driving repeat purchases among gastroenterology practices. Clinical research claims roughly 18 % of device placements; here, sponsors favor wireless capsules for 48-hour ambulatory protocols that reduce dropout versus catheter-based studies. Hospitals, the third cluster, absorb ~15 % of annual shipments; procurement is driven by high-throughput endoscopy units that amortize capital costs across multiple departments. Ambulatory Surgical Centers (ASCs) contribute ~12 %, leveraging same-day discharge codes to shorten payback cycles. Homecare settings, growing at 9 % share, are pulled by reimbursement for remote reflux monitoring, while other niche applications (oropharyngeal reflux, esophageal function testing) round out the remaining 4 %. Each sub-segment’s reimbursement landscape, procedure volume elasticity and capital budget cycles collectively determine its contribution to overall Wireless PH Monitoring Systems market size.